{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T18:06:18Z","timestamp":1784225178917,"version":"3.55.0"},"reference-count":60,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To systematically characterize the post-marketing safety signals of isotretinoin using real-world data from the U.S. FDA Adverse Event Reporting System (FAERS), with independent external validation in the European EudraVigilance (EV) database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adverse event (AE) reports in FAERS from 2004Q1 to 2024Q3 were analyzed. Signal detection was conducted using four complementary disproportionality algorithms: reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and the multi-item gamma Poisson shrinker (MGPS). Signals concurrently detected by all four methods were defined as robust. Key findings were subsequently examined in EV as an external reference.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 50,519 patients contributing 142,160 isotretinoin-associated AE reports, 469 statistically robust signals were identified, spanning 25 system organ classes (SOCs). Signals were most concentrated in psychiatric disorders (75, 15.99%), gastrointestinal disorders (58, 12.37%), and congenital, familial, and genetic disorders (50, 10.66%). The strongest association was observed for inflammatory bowel disease (IBD; ROR\u2009=\u2009579.14); however, temporal clustering and reporter-type profiling suggested substantial stimulated reporting, potentially driven by litigation, warranting cautious interpretation. Several high-ranking signals were not described in current product labeling, including nasal vestibulitis, hypertrophic anal papilla, and SAPHO syndrome. Pregnancy-related signals were prominent, with unintended pregnancy showing a strong signal (ROR\u2009=\u200991.39). External validation in EV demonstrated high concordance, supporting the robustness and reproducibility of the findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Isotretinoin is associated with a broad spectrum of pharmacovigilance signals, with disproportionate representation of psychiatric, gastrointestinal, and pregnancy-related events. While multiple previously unlabelled signals emerged, their clinical relevance remains to be established. These findings underscore the need for strengthened clinical monitoring, rigorous pregnancy prevention strategies, and careful interpretation of spontaneous reporting data.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0329161","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T17:39:01Z","timestamp":1784223541000},"page":"e0329161","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Signal mining and analysis of adverse events associated with Isotretinoin: A 20-Year real-world pharmacovigilance study based on FAERS and EudraVigilance databases"],"prefix":"10.1371","volume":"21","author":[{"given":"Qian","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JinYue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XueDong","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LiZhu","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2365-9177","authenticated-orcid":true,"given":"Yuan","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2973-5612","authenticated-orcid":true,"given":"HongLi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"pone.0329161.ref001","first-page":"583","article-title":"Guideline for diagnosis and treatment of acne (the 2019 revised edition)","volume":"48","author":"Q Ju","year":"2019","journal-title":"J Clinical Dermatol"},{"issue":"15","key":"pone.0329161.ref002","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1056\/NEJMicm2406625","article-title":"Acne Fulminans","volume":"391","author":"H-H Hu","year":"2024","journal-title":"N Engl J Med"},{"issue":"20","key":"pone.0329161.ref003","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1001\/jama.2021.17633","article-title":"Management of Acne Vulgaris: A Review","volume":"326","author":"DZ Eichenfield","year":"2021","journal-title":"JAMA"},{"key":"pone.0329161.ref004","first-page":"573","article-title":"Guideline for the diagnosis and treatment of psoriasis in China (2023 edition)","volume":"56","author":"Committee on Psoriasis CS of D","year":"2023","journal-title":"Chinese J Dermatol"},{"key":"pone.0329161.ref005","first-page":"149","article-title":"Guideline for diagnosis and treatment of cutaneous lupus erythematosus","volume":"52","author":"Lupus Erythematosus Research Center of Chinese Society of Dermatology","year":"2019","journal-title":"Chinese J Dermatol"},{"issue":"1","key":"pone.0329161.ref006","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jaad.2021.08.047","article-title":"Executive summary: Consensus recommendations for the use of retinoids in ichthyosis and other disorders of cornification in children and adolescents","volume":"86","author":"PeDRA Use of Retinoids in Ichthyosis Work Group","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"pone.0329161.ref007","first-page":"588","article-title":"Expert consensus on diagnosing and treating of neuroblastoma in children: CCCG-NB-2021 regime","volume":"43","author":"Pediatric Oncology Committee CA-CA, Oncology Group CA of PS","year":"2022","journal-title":"Chinese Journal of Pediatric Surgery"},{"issue":"5","key":"pone.0329161.ref008","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jaad.2024.06.068","article-title":"Association of inflammatory bowel disease incidence with isotretinoin usage: A meta-analysis and systematic review","volume":"91","author":"A Ahmed","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"pone.0329161.ref009","article-title":"Association between opioid analgesics and learning disorders: a disproportionality analysis of the FDA adverse event reporting system (FAERS) and EudraVigilance databases","author":"Z Feng","year":"2025","journal-title":"Int J Surg"},{"issue":"7","key":"pone.0329161.ref010","doi-asserted-by":"crossref","first-page":"454","DOI":"10.2174\/0113894501290296240327081624","article-title":"Drug Repurposing Using FDA Adverse Event Reporting System (FAERS) Database","volume":"25","author":"R Morris","year":"2024","journal-title":"Curr Drug Targets"},{"issue":"6","key":"pone.0329161.ref011","article-title":"The adverse events of toripalimab in nasopharyngeal carcinoma based on FAERS database and bibliometric analysis","volume":"20","author":"Q Guo","year":"2025","journal-title":"PLoS One"},{"issue":"5","key":"pone.0329161.ref012","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0323973","article-title":"Real-world safety assessment of Ixekizumab based on the FDA Adverse Event Reporting System (FAERS)","volume":"20","author":"Y Cheng","year":"2025","journal-title":"PLoS One"},{"issue":"2","key":"pone.0329161.ref013","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/bjd.19477","article-title":"Reviewing the global burden of acne: how could we improve care to reduce the burden?","volume":"184","author":"AM Layton","year":"2021","journal-title":"Br J Dermatol"},{"key":"pone.0329161.ref014","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/bjd\/ljae352","article-title":"Global, regional and national burdens of acne vulgaris in adolescents and young adults aged 10-24\u2005years from 1990 to 2021: a trend analysis","volume":"192","author":"Z Zhu","year":"2025","journal-title":"Br J Dermatol"},{"issue":"1","key":"pone.0329161.ref015","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jaad.2024.06.069","article-title":"JAAD Game Changers: Adult female acne and associated risk factors: Results of a multicenter case-control study in Italy","volume":"92","author":"E Lake","year":"2025","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"pone.0329161.ref016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0290763","article-title":"Acne accounts for an almost 2.5-fold higher proportion of dermatology visits among adult females compared to adult males in the United States: A study of the national ambulatory medical care survey from 2002-2016","volume":"18","author":"J Chang","year":"2023","journal-title":"PLoS One"},{"issue":"11","key":"pone.0329161.ref017","doi-asserted-by":"crossref","first-page":"6463","DOI":"10.3390\/ijerph19116463","article-title":"Adverse Events in Isotretinoin Therapy: A Single-Arm Meta-Analysis","volume":"19","author":"J Kapa\u0142a","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"pone.0329161.ref018","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s40257-020-00508-0","article-title":"Optimizing isotretinoin treatment of acne: update on current recommendations for monitoring, dosing, safety, adverse effects, compliance, and outcomes","volume":"21","author":"MN Landis","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"pone.0329161.ref019","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.curtheres.2019.01.008","article-title":"Psychiatric and developmental effects of isotretinoin (Retinoid) treatment for acne vulgaris","volume":"90","author":"A Suuberg","year":"2019","journal-title":"Curr Ther Res Clin Exp"},{"issue":"10","key":"pone.0329161.ref020","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1001\/jamadermatol.2019.1416","article-title":"Psychiatric adverse events in patients taking isotretinoin as reported in a food and drug administration database from 1997 to 2017","volume":"155","author":"S Singer","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"2","key":"pone.0329161.ref021","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.jaad.2020.02.040","article-title":"Acne vulgaris and risk of depression and anxiety: A meta-analytic review","volume":"83","author":"DV Samuels","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"pone.0329161.ref022","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2023.01.038","article-title":"Reply to: \u201cInterpreting with caution the lack of association between isotretinoin, depression, and suicide\u201d","volume":"89","author":"K Kridin","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"pone.0329161.ref023","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1001\/jamadermatol.2023.4579","article-title":"Risk of suicide and psychiatric disorders among isotretinoin users: a meta-analysis","volume":"160","author":"NKW Tan","year":"2024","journal-title":"JAMA Dermatol"},{"issue":"3","key":"pone.0329161.ref024","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jaad.2013.04.031","article-title":"Alleged isotretinoin-associated inflammatory bowel disease: disproportionate reporting by attorneys to the Food and Drug Administration Adverse Event Reporting System","volume":"69","author":"DJ Stobaugh","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"pone.0329161.ref025","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/ajg.2014.34","article-title":"Isotretinoin and inflammatory bowel disease: trial lawyer misuse of science and FDA warnings","volume":"109","author":"S Tenner","year":"2014","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"pone.0329161.ref026","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s40257-023-00765-9","article-title":"Isotretinoin exposure and risk of inflammatory bowel disease: a systematic review with meta-analysis and trial sequential analysis","volume":"24","author":"C-L Yu","year":"2023","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"pone.0329161.ref027","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.jaad.2022.12.015","article-title":"Isotretinoin and the risk of inflammatory bowel disease and irritable bowel syndrome: A large-scale global study","volume":"88","author":"K Kridin","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"pone.0329161.ref028","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1001\/jamadermatol.2013.1348","article-title":"The weight of evidence on the association of isotretinoin use and the development of inflammatory bowel disease","volume":"149","author":"CM Popescu","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"4","key":"pone.0329161.ref029","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jaad.2023.01.014","article-title":"A propensity score matched cohort study identifying an association of acne, but not oral antibiotic or isotretinoin use, with risk of incident inflammatory bowel disease","volume":"88","author":"MT Taylor","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"pone.0329161.ref030","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/bjd.14053","article-title":"Pregnancy outcomes following first-trimester exposure to topical retinoids: a systematic review and meta-analysis","volume":"173","author":"YC Kaplan","year":"2015","journal-title":"Br J Dermatol"},{"key":"pone.0329161.ref031","article-title":"Challenges to contraceptive counseling with isotretinoin treatment and future directions for dermatologists","volume":"2","author":"A Greene","year":"2024","journal-title":"Clin Dermatol Surg"},{"issue":"4","key":"pone.0329161.ref032","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/aogs.15052","article-title":"Exposure to potentially teratogenic medications before and during the first trimester of pregnancy compared to women of childbearing age: A retrospective analysis of Swiss claims data (2015-2021)","volume":"104","author":"CA Marxer","year":"2025","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"6","key":"pone.0329161.ref033","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1093\/brain\/awaf094","article-title":"Fetal malformations of cortical development: review and clinical guidance","volume":"148","author":"JB Russ","year":"2025","journal-title":"Brain"},{"issue":"5","key":"pone.0329161.ref034","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1080\/09546634.2021.1967269","article-title":"Isotretinoin for acne vulgaris - an update on adverse effects and laboratory monitoring","volume":"33","author":"H Fallah","year":"2022","journal-title":"J Dermatolog Treat"},{"issue":"6","key":"pone.0329161.ref035","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00403-024-03070-5","article-title":"Contraceptive counseling for iPLEDGE and its burden on dermatologists","volume":"316","author":"KE Owens","year":"2024","journal-title":"Arch Dermatol Res"},{"issue":"3","key":"pone.0329161.ref036","doi-asserted-by":"crossref","first-page":"377","DOI":"10.15171\/apb.2018.044","article-title":"Isotretinoin; a review on the utilization pattern in pregnancy","volume":"8","author":"S Khiali","year":"2018","journal-title":"Adv Pharm Bull"},{"issue":"9","key":"pone.0329161.ref037","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/ijd.13950","article-title":"A comparative review of the isotretinoin pregnancy risk management programs across four continents","volume":"57","author":"T Kovitwanichkanont","year":"2018","journal-title":"Int J Dermatol"},{"issue":"1","key":"pone.0329161.ref038","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004339","article-title":"Use of isotretinoin among girls and women of childbearing age and occurrence of isotretinoin-exposed pregnancies in Germany: A population-based study","volume":"21","author":"J Reinold","year":"2024","journal-title":"PLoS Med"},{"issue":"1","key":"pone.0329161.ref039","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40801-023-00381-3","article-title":"Compliance with pregnancy prevention recommendations for isotretinoin following the amendment of the european union pregnancy prevention program: a repeat study in Estonia","volume":"11","author":"M Ivask","year":"2024","journal-title":"Drugs Real World Outcomes"},{"issue":"10","key":"pone.0329161.ref040","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.3390\/jcm14103497","article-title":"Compliance with the european pregnancy prevention programme in isotretinoin treatment: safety outcomes and dose-related correlations","volume":"14","author":"P Brzezi\u0144ski","year":"2025","journal-title":"J Clin Med"},{"issue":"2","key":"pone.0329161.ref041","doi-asserted-by":"crossref","first-page":"201","DOI":"10.5468\/ogs.20247","article-title":"Non-compliance with pregnancy prevention recommendations for isotretinoin in Korea between 2019-2020","volume":"64","author":"EJ Choi","year":"2021","journal-title":"Obstet Gynecol Sci"},{"key":"pone.0329161.ref042","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/jdv.20073","article-title":"Compliance with the pregnancy prevention program among women initiating isotretinoin treatment between 2014 and 2021: a nationwide cohort study on the french health data system (SNDS)","volume":"39","author":"A Havet","year":"2025","journal-title":"J Eur Acad Dermatol Venereol: JEADV"},{"issue":"1","key":"pone.0329161.ref043","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.bjorl.2018.10.004","article-title":"Effects of oral isotretinoin therapy on the nasal cavities","volume":"86","author":"H Tasli","year":"2020","journal-title":"Braz J Otorhinolaryngol"},{"issue":"8","key":"pone.0329161.ref044","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1177\/0145561320920425","article-title":"Evaluation of nasal mucociliary clearance, nasal obstruction symptom evaluation, and epistaxis severity score in isotretinoin treatment","volume":"100","author":"A \u0130\u015flek","year":"2021","journal-title":"Ear Nose Throat J"},{"issue":"6","key":"pone.0329161.ref045","doi-asserted-by":"crossref","DOI":"10.1152\/ajpgi.00567.2006","article-title":"Chronically administered retinoic acid has trophic effects in the rat small intestine and promotes adaptation in a resection model of short bowel syndrome","volume":"292","author":"L Wang","year":"2007","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"2","key":"pone.0329161.ref046","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s41385-018-0074-8","article-title":"Correction: Intestinal epithelial cell-specific RAR\u03b1 depletion results in aberrant epithelial cell homeostasis and underdeveloped immune system","volume":"12","author":"HB Jijon","year":"2019","journal-title":"Mucosal Immunol"},{"issue":"4","key":"pone.0329161.ref047","first-page":"457","article-title":"Retinoic acid suppresses intestinal mucus production and exacerbates experimental enterocolitis","volume":"5","author":"SH Oehlers","year":"2012","journal-title":"Dis Model Mech"},{"issue":"3","key":"pone.0329161.ref048","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3390\/jpm11030211","article-title":"Differentiating Neuroblastoma: a systematic review of the retinoic acid, its derivatives, and synergistic interactions","volume":"11","author":"N Bayeva","year":"2021","journal-title":"J Pers Med"},{"issue":"1","key":"pone.0329161.ref049","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/exd.13420","article-title":"Overexpression of p53 explains isotretinoin\u2019s teratogenicity","volume":"27","author":"BC Melnik","year":"2018","journal-title":"Exp Dermatol"},{"issue":"7","key":"pone.0329161.ref050","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1200\/JCO.2007.13.8925","article-title":"Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children\u2019s oncology group study","volume":"27","author":"KK Matthay","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"pone.0329161.ref051","doi-asserted-by":"crossref","first-page":"544","DOI":"10.3390\/cancers16030544","article-title":"Retinoid therapy for neuroblastoma: historical overview, regulatory challenges, and prospects","volume":"16","author":"A Makimoto","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"2","key":"pone.0329161.ref052","doi-asserted-by":"crossref","DOI":"10.1097\/MPH.0b013e318290c39e","article-title":"Congenital neuroblastoma in a neonate with isotretinoin embryopathy","volume":"36","author":"S Aguilar","year":"2014","journal-title":"J Pediatr Hematol Oncol"},{"issue":"3","key":"pone.0329161.ref053","doi-asserted-by":"crossref","DOI":"10.1093\/bjsopen\/zrae032","article-title":"Genetic, epigenetic and environmental factors in diverticular disease: systematic review","volume":"8","author":"HN Humphrey","year":"2024","journal-title":"BJS Open"},{"issue":"5","key":"pone.0329161.ref054","doi-asserted-by":"crossref","first-page":"581","DOI":"10.3390\/genes16050581","article-title":"Genetic determinants of colonic diverticulosis-a systematic review","volume":"16","author":"P Nehring","year":"2025","journal-title":"Genes (Basel)"},{"key":"pone.0329161.ref055","doi-asserted-by":"crossref","first-page":"1427784","DOI":"10.3389\/fimmu.2024.1427784","article-title":"The role of cytokines in the pathogenesis of SAPHO syndrome","volume":"15","author":"Y Yang","year":"2024","journal-title":"Front Immunol"},{"key":"pone.0329161.ref056","doi-asserted-by":"crossref","first-page":"1560398","DOI":"10.3389\/fimmu.2025.1560398","article-title":"Therapeutic approaches for SAPHO syndrome from the perspective of pathogenesis: a review of the literature","volume":"16","author":"Y Wang","year":"2025","journal-title":"Front Immunol"},{"issue":"4","key":"pone.0329161.ref057","article-title":"Treatment and monitoring of SAPHO syndrome: a systematic review","volume":"9","author":"SWS Li","year":"2023","journal-title":"RMD Open"},{"issue":"1","key":"pone.0329161.ref058","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s13052-020-00933-1","article-title":"SAPHO syndrome: the supposed trigger by isotretinoin, the efficacy of adalimumab and the specter of depressive disorder: a case report","volume":"46","author":"M Luzzati","year":"2020","journal-title":"Ital J Pediatr"},{"issue":"3","key":"pone.0329161.ref059","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/cpt.3701","article-title":"FDA adverse event reporting system (FAERS) essentials: a guide to understanding, applying, and interpreting adverse event data reported to FAERS","volume":"118","author":"E Potter","year":"2025","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"pone.0329161.ref060","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.clinthera.2020.03.018","article-title":"Signal management in pharmacovigilance: a review of activities and case studies","volume":"42","author":"P Beninger","year":"2020","journal-title":"Clin Ther"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0329161","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T17:39:13Z","timestamp":1784223553000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0329161"}},"subtitle":[],"editor":[{"given":"Gisele Viana de","family":"Oliveira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":60,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0329161","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]}}}